<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04424485</url>
  </required_header>
  <id_info>
    <org_study_id>B.10.1.TKH.4.34.H.GP.0.01/213</org_study_id>
    <nct_id>NCT04424485</nct_id>
  </id_info>
  <brief_title>Near-infrared Fluorescence With Indocyanine Green for Identification of Sentinels and Parathyroids During Thyroidectomy</brief_title>
  <official_title>Near-infrared (NIR) Fluorescence Imaging With Indocyanine Green (ICG) for Identification of Sentinel Lymph Nodes and Parathyroid Glands During Total Thyroidectomy: Prospective Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umraniye Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Umraniye Education and Research Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Indocyanine green (ICG) is a water-soluble organic dye that is cleared totally through the
      hepatobiliary system. It has a half-life of 3-4 mins, which allows repeated applications.
      Near-infrared (NIR) fluorescence imaging with indocyanine green (ICG) imaging has been
      recently introduced, and has been suggested as a useful tool for the identification and
      preservation of the parathyroid glands (PGs) during total thyroidectomy (TT). ICG can also be
      used for sentinel lymph node (SLN) biopsy to predict the micrometastases in central lymph
      nodes (CLN) in thyroid carcinoma, and central lymph node dissection can reduce local
      recurrence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Incidence of thyroid cancer has doubled between 1980 and 2020, and it is now the fifth most
      common malignant tumor among women. The majority are papillary thyroid cancer (PTC), and TT
      is the procedure of choice. Since the micrometastasis rate of the central lymph nodes (CLNs)
      is about 30% to 90% in PTC, CLN dissection can improve the prognosis and reduce tumor
      recurrence as well as provide accurate information for the evaluation of tumor staging.
      However, TT procedure has some important complications such as vocal cord paralysis (VCP) and
      hypocalcemia (due to accicental parathyroidectomy or damage to the parathyroid gland-PG-
      vasculature). Use of intraoperative nerve monitoring (IONM) has reduced the rate of VCP.
      However, the incidence of postoperative hypocalcemia is still high (15-70%), and it is now
      the most common complication of TT. Intraoperative identification of SLNs and PGs can help
      surgeon to overcome these problems.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Involvement of sentinel lymph node (presence/absence of tumor cell: positive or negative) by histopathological examinatiion</measure>
    <time_frame>1 year</time_frame>
    <description>Intrathyroidal injection of indocyanine green (ICG) dye to identify sentinel lymph node (SLN) for biopsy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of parathyroid glands (PGs) by NIR/ICG camera detected high-contrast</measure>
    <time_frame>1 year</time_frame>
    <description>Ä°ntravenous injection of ICG dye, to identify PGs under NIR (High-contrast fluorescence seen or not)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central lymph node dissetion (CLND)</measure>
    <time_frame>1 year</time_frame>
    <description>Number of positive lymph nodes (micrometastases)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Thyroid Cancer</condition>
  <condition>Thyroid Carcinoma, Papillary</condition>
  <condition>Thyroid Metastases</condition>
  <condition>Thyroid Neoplasms</condition>
  <condition>Sentinel Lymph Node</condition>
  <condition>Lymph Node Metastases</condition>
  <arm_group>
    <arm_group_label>Thyroid carcinoma patients (biopsy-proven)-Total thyroidectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group-Total thyroidectomy (TT) with central lymph node dissection (CLND) procedure for patients with papillary thyroid carcinoma (PTC)
Standard TT+CLND procedure only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thyroid carcinoma patients (biopsy-proven)-Sentinel lymph node</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group- Sentinel lymph node dissection (SLND) after intratumoral indocyanine green (ICG) injection and visualization of all 4 parathyroid glands with infra-red (NIR) fluorescence after intravenous (iv) ICG injection, during total thyroidectomy and central lymph node dissection (CLND).
TT+CLND with NIR fluorescence ICG</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total thyroidectomy (TT)</intervention_name>
    <description>Standard TT procedure for thyroid carcinoma, for both groups</description>
    <arm_group_label>Thyroid carcinoma patients (biopsy-proven)-Sentinel lymph node</arm_group_label>
    <arm_group_label>Thyroid carcinoma patients (biopsy-proven)-Total thyroidectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Central lymph node dissection (CLND)</intervention_name>
    <description>Standard CLND for thyroid carcinoma, for both groups</description>
    <arm_group_label>Thyroid carcinoma patients (biopsy-proven)-Sentinel lymph node</arm_group_label>
    <arm_group_label>Thyroid carcinoma patients (biopsy-proven)-Total thyroidectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sentinel lymph node (SLN) bopsy</intervention_name>
    <description>Intrathyroidal injection of ICG for SL biopsy, for only experimental group</description>
    <arm_group_label>Thyroid carcinoma patients (biopsy-proven)-Sentinel lymph node</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Identification of parathyroid glands (PGs)</intervention_name>
    <description>Near-infrared (NIR) fluorescence visualization of PGs, for only experimental group</description>
    <arm_group_label>Thyroid carcinoma patients (biopsy-proven)-Sentinel lymph node</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Thyroid carcinoma patients (biopsy/cytology-proven) suitable for total thyroidectomy
             procedure

          -  Patients at or over 17 years

        Exclusion Criteria:

          -  Previous thyroid surgery

          -  Patients below 17 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ethem Unal, MD, PhD, USMLE&amp;IFSO-CSS, A. Prof.</last_name>
    <phone>+90 216 632 1818</phone>
    <phone_ext>1950</phone_ext>
    <email>drethemunal@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sema Yuksekdag, MD</last_name>
    <phone>+90 216 632 1818</phone>
    <phone_ext>1950</phone_ext>
    <email>drsemayuksekdag@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Umraniye Education and Research Hospital, Department of General Surgery</name>
      <address>
        <city>Istanbul</city>
        <zip>34760</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ethem Unal, MD, PhD, A. Prof. of Surgery &amp; Surgical Oncology</last_name>
      <phone>+90 216 632 1818</phone>
      <phone_ext>1950</phone_ext>
      <email>drethemunal@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sema Yuksekdag, MD</last_name>
      <phone>+90 216 632 1818</phone>
      <phone_ext>1950</phone_ext>
      <email>drsemayuksekdag@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>https://scholar.google.com.tr/citations?user=6bFlCZwAAAAJ&amp;hl=tr</url>
    <description>Ethem Unal</description>
  </link>
  <results_reference>
    <citation>Zhang X, Shen YP, Li JG, Chen G. Clinical feasibility of imaging with indocyanine green combined with carbon nanoparticles for sentinel lymph node identification in papillary thyroid microcarcinoma. Medicine (Baltimore). 2019 Sep;98(36):e16935. doi: 10.1097/MD.0000000000016935.</citation>
    <PMID>31490376</PMID>
  </results_reference>
  <results_reference>
    <citation>Spartalis E, Ntokos G, Georgiou K, Zografos G, Tsourouflis G, Dimitroulis D, Nikiteas NI. Intraoperative Indocyanine Green (ICG) Angiography for the Identification of the Parathyroid Glands: Current Evidence and Future Perspectives. In Vivo. 2020 Jan-Feb;34(1):23-32. doi: 10.21873/invivo.11741. Review.</citation>
    <PMID>31882459</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 2, 2020</study_first_submitted>
  <study_first_submitted_qc>June 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Umraniye Education and Research Hospital</investigator_affiliation>
    <investigator_full_name>Ethem Unal, M.D., PhD, Associate Prof of Surgery &amp; Surgic</investigator_full_name>
    <investigator_title>A. Prof. of General Surgery and Surgical Oncology</investigator_title>
  </responsible_party>
  <keyword>Near-infrared (NIR) fluorescence</keyword>
  <keyword>Total thyroidectomy</keyword>
  <keyword>Parathyroid glands</keyword>
  <keyword>Indocyanine green (ICG)</keyword>
  <keyword>Central lymph node dissection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Papillary</mesh_term>
    <mesh_term>Thyroid Cancer, Papillary</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parathyroid Hormone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Excel data is available upon request at drethemunal@gmail.com</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>1 year</ipd_time_frame>
    <ipd_access_criteria>Please request study protocol and data (when available) at drethemunal@gmail.com</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

